Effects of Total Glycosides of Cistanche deserticola on HepG2 Hepatoma-Bearing Mice
, Wenjie YAN1(
)Abstract
To study the anti-tumor effect of Cistanche deserticola in Balb/c mice, tumor-bearing nude mice subcutaneously inoculated with HepG2 liver cancer cells were administered with total glycosides (TG) of C. deserticola at different doses by gavage. The pathological changes in the liver and tumors, the proliferation capacity of splenic lymphocytes, and antioxidant indicators in the liver were detected. Metabolomics and 16S rDNA sequencing were used to analyze the changes in metabolites and microbial community composition in the intestinal contents of mice. Results showed that TG inhibited the growth of tumor in nude mice without affecting the normal growth and development of the mice and without any toxic side effects. As the dose of TG increased, the structure of hepatocytes in liver tissues became intact, the degree of pathological changes gradually reduced, the distribution of tumor cells became sparser, and the degree of vacuole deformation increased, which was accompanied by the occurrence of necrosis, indicating that TG could protect the liver and simultaneously inhibit the growth of tumor. TG alleviated liver lesions in mice, as evidenced by increased levels of catalase (CAT) and glutamic-pyruvic transaminase (GPT) and decreased levels of aspartate aminotransferase (GOT) and alkaline phosphatase (AKP). With increasing TG dose, the proliferative capacity of lymphocytes also increased, indicating that TG could exert an anti-liver cancer effect by improving immune function in mice. In addition, TG could inhibit the progression of liver cancer by regulating the levels of metabolites and improving the composition of the intestinal microbiota. Therefore, TG of C. deserticola has an anti-liver cancer effect by improving oxidative stress resistance, regulating immune capacity, improving the metabolic profile and regulating intestinal microbial balance.
References
SONG Y L, ZENG K W, JIANG Y, et al. Cistanches Herba, from an endangered species to a big brand of Chinese medicine[J]. Medicinal Research Reviews, 2021, 41(3): 1539-1577. DOI:10.1002/med.21768.
WANG N Q, JI S Z, ZHANG H, et al. Herba Cistanches: anti-aging[J]. Aging and Disease, 2017, 8(6): 740-759. DOI:10.14336/AD.2017.0720.
ZHOU S Q, FENG D, ZHOU Y X, et al. Analysis of the active ingredients and health applications of cistanche[J]. Frontiers in Nutrition, 2023, 10: 1101182. DOI:10.3389/fnut.2023.1101182.
BI C C, XIAO G Q, LIU C Y, et al. Molecular immune mechanism of intestinal microbiota and their metabolites in the occurrence and development of liver cancer[J]. Frontiers in Cell and Developmental Biology, 2021, 9: 702414. DOI:10.3389/fcell.2021.702414.
CHEN W, WEN L, BAO Y Y, et al. Gut flora disequilibrium promotes the initiation of liver cancer by modulating tryptophan metabolism and up-regulating SREBP2[J]. Proceedings of National Academy of Sciences of the United States of America, 2022, 119(52): e2203894119. DOI:10.1073/pnas.2203894119.
GIRAUD J, SALEH M. Host-microbiota interactions in liver inflammation and cancer[J]. Cancers, 2021, 13(17): 4342. DOI:10.3390/cancers13174342.
GUPTA H, YOUN G S, SHIN M J, et al. Role of gut microbiota in hepatocarcinogenesis[J]. Microorganisms, 2019, 7(5): 4342. DOI:10.3390/microorganisms7050121.
SCHNEIDER K M, MOHS A, GUI W, et al. Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment[J]. Nature Communiations, 2022, 13(1): 3964. DOI:10.1038/s41467-022-31312-5.
GAO Y Q, QIN G Q, WEN P J, et al. Safety assessment of powdered Cistanche deserticola Y. C. Ma by a 90-day feeding test in sprague-dawley rats[J]. Drug and Chemical Toxicology, 2017, 40(4): 383-389. DOI:10.1080/01480545.2016.1242013.
GEORGE P. Reaction between catalase and hydrogen peroxide[J]. Nature, 1947, 160: 41-43. DOI:10.1038/160041a0.
LIU J K, GENG W, SUN H Y, et al. Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma[J]. Gut, 2022, 71(6): 1203-1213. DOI:10.1136/gutjnl-2021-325189.
CHEN W, YANG W J, ZHANG C Y, et al. Modulation of the p38 MAPK pathway by anisomycin promotes ferroptosis of hepatocellular carcinoma through phosphorylation of H3S10[J]. Oxidative Medicine and Cellular Longevity, 2022, 2022: 6986445. DOI:10.1155/2022/6986445.
ALAVIFARD H, MAZHARI S, MEYFOUR A, et al. Imatinib suppresses activation of hepatic stellate cells by targeting STAT3/IL-6 pathway through miR-124[J]. Cell Biolpgy International, 2023, 47(5): 969-980. DOI:10.1002/cbin.11992.
ZHANG Q, JU Y H, ZHANG Y, et al. The water expelling effect evaluation of 3-O-(2’E,4’Z-decadienoyl)-20-O-acetylingenol and ingenol on H22 mouse hepatoma ascites model and their content differences analysis in Euphorbia kansui before and after stir-fried with vinegar by UPLC[J]. Journal of Ethnopharmacol, 2021, 267: 113507. DOI:10.1016/j.jep.2020.113507.
NAIR G, HEMA SREE G N S, SARASWATHY G R, et al. Application of comprehensive bioinformatics approaches to reconnoiter crucial genes and pathways underpinning hepatocellular carcinoma: a drug repurposing endeavor[J]. Medical Oncology, 2021, 38(12): 145. DOI:10.1007/s12032-021-01576-w.
LUO M J, LIU Y F, LIU N N, et al. Proscillaridin A inhibits hepatocellular carcinoma progression through inducing mitochondrial damage and autophagy[J]. Acta Biochimica Biophysica Sinica, 2021, 53(1): 19-28. DOI:10.1093/abbs/gmaa139.
GAO Y, LI B, LIU H, et al. Cistanche deserticola polysaccharides alleviate cognitive decline in aging model mice by restoring the gut microbiota-brain axis[J]. Aging, 2021, 13(11): 15320-15335. DOI:10.18632/aging.203090.
NAGASAKI A, SAKAMOTO S, ARAI T, et al. Elimination of porphyromonas gingivalis inhibits liver fibrosis and inflammation in NASH[J]. Journal of Clinical Periodontology, 2021, 48(10): 1367-1378. DOI:10.1111/jcpe.13523.
QI Y F, SUN J N, REN L F, et al. Intestinal microbiota is altered in patients with gastric cancer from Shanxi province, China[J]. Digestive Diseases and Sciences, 2019, 64(5): 1193-1203. DOI:10.1007/s10620-018-5411-y.
MU H N, ZHOU Q, YANG R Y, et al. Naringin attenuates high fat diet induced non-alcoholic fatty liver disease and gut bacterial dysbiosis in mice[J]. Frontiers in Microbiology, 2020, 11: 585066. DOI:10.3389/fmicb.2020.585066.
京公网安备11010802044758号